Table 2 Summary of current mouse models... | American Society of Hematology

Table 2

Summary of current mouse models for MA4⁺ B-ALL

Strategy	Phenotype*	Latency†	Tissue-specific Cre	Reference
Constitutive Mll-AF4 knock-in mice	Myeloproliferative/follicular B leukemia	520 days (17 months)	NA	Chen et al¹⁰⁹
Mll-AF4 invertor mice	B-cell lineage neoplasias	317-466 days	Rag-Cre	Metzler et al¹¹⁰
		416-472 days	Lck-Cre	Metzler et al¹¹⁰
		460-475 days	CD19-Cre
Conditional Mll-AF4 knock-in mice	B-precursor ALL and AML	131 days	Mx1-Cre	Krivtsov et al⁹⁸
Transplant of AF4-MLL-transduced murine HSPCs	AF4-MLL: pro-B ALL (63%); B/T biphenotypic (37%)	AF4-MLL: 233 days	NA	Bursen et al⁸³
	AF4-MLL: pro-B ALL (63%); B/T biphenotypic (37%)	Double: 266 days
	Double: B/T biphenotypic (67%); pro-B ALL (33%)	Double: 266 days
MLL-AF4 transgenic mice	Lymphoblastic leukemia or lymphoma	12 months	NA	Tamai et al¹¹¹

Strategy	Phenotype*	Latency†	Tissue-specific Cre	Reference
Constitutive Mll-AF4 knock-in mice	Myeloproliferative/follicular B leukemia	520 days (17 months)	NA	Chen et al¹⁰⁹
Mll-AF4 invertor mice	B-cell lineage neoplasias	317-466 days	Rag-Cre	Metzler et al¹¹⁰
		416-472 days	Lck-Cre	Metzler et al¹¹⁰
		460-475 days	CD19-Cre
Conditional Mll-AF4 knock-in mice	B-precursor ALL and AML	131 days	Mx1-Cre	Krivtsov et al⁹⁸
Transplant of AF4-MLL-transduced murine HSPCs	AF4-MLL: pro-B ALL (63%); B/T biphenotypic (37%)	AF4-MLL: 233 days	NA	Bursen et al⁸³
	AF4-MLL: pro-B ALL (63%); B/T biphenotypic (37%)	Double: 266 days
	Double: B/T biphenotypic (67%); pro-B ALL (33%)	Double: 266 days
MLL-AF4 transgenic mice	Lymphoblastic leukemia or lymphoma	12 months	NA	Tamai et al¹¹¹

NA, not applicable.

Disease phenotype observed differs from pro-B ALL (CD10⁻).

Latency, defined as time to leukemia development, is always very protracted.